MARKET

AURA

AURA

AURA BIOSCIENCES INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.40
-0.05
-0.30%
After Hours: 16.40 0 0.00% 16:00 01/14 EST
OPEN
16.00
PREV CLOSE
16.45
HIGH
16.40
LOW
15.80
VOLUME
18.52K
TURNOVER
--
52 WEEK HIGH
26.16
52 WEEK LOW
13.50
MARKET CAP
479.05M
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
50 Biggest Movers From Yesterday
Gainers
Benzinga · 11/30/2021 09:45
Aura Biosciences EPS misses by $27.88
Aura Biosciences (NASDAQ:AURA): Q3 GAAP EPS of -$28.33 misses by $27.88. As of September 30, 2021, Aura had cash and cash equivalents totaling $81.8 million. Aura raised $86.9 million in
Seekingalpha · 11/24/2021 21:26
BTIG initiates Aura Biosciences with a buy on targeted oncology approach
BTIG has initiated Aura Biosciences (NASDAQ:AURA) with a buy rating citing the company's novel targeted oncology platform. The firm has a $38 price target (~112% upside). Analyst Bert Hazlett speaks
Seekingalpha · 11/24/2021 14:34
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., November 23, 2021--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers,...
Business Wire · 11/23/2021 21:05
Aura Biosciences slips despite bullish views from analysts on expiry of quiet period
Aura Biosciences (AURA -7.9%) is trading lower despite buy-equivalent ratings issued by several Wall Street analysts as the company faces the expiry of its post-IPO quiet period. BTIG analyst Bert
Seekingalpha · 11/23/2021 17:23
BTIG Initiates Coverage On Aura Biosciences with Buy Rating, Announces Price Target of $38
BTIG analyst Robert Hazlett initiates coverage on Aura Biosciences (NASDAQ:AURA) with a Buy rating and announces Price Target of $38.
Benzinga · 11/23/2021 14:37
Evercore ISI Group Initiates Coverage On Aura Biosciences with Outperform Rating, Announces Price Target of $35
Evercore ISI Group analyst Liisa Bayko initiates coverage on Aura Biosciences (NASDAQ:AURA) with a Outperform rating and announces Price Target of $35.
Benzinga · 11/23/2021 12:21
Cowen & Co. Initiates Coverage On Aura Biosciences with Outperform Rating
Cowen & Co. analyst Phil Nadeau initiates coverage on Aura Biosciences (NASDAQ:AURA) with a Outperform rating.
Benzinga · 11/23/2021 12:14
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AURA. Analyze the recent business situations of AURA BIOSCIENCES INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Director
David Johnson
Chief Executive Officer/Director
Elisabet de los Pinos
Chief Financial Officer/Primary Contact
Julie Feder
Chief Operating Officer
Mark De Rosch
Other
Cadmus Rich
No Data
About AURA
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The Company's VDC platform offers a range of portfolio of targeted oncology therapeutics. It engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).

Webull offers kinds of Aura Biosciences Inc stock information, including NASDAQ:AURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AURA stock methods without spending real money on the virtual paper trading platform.